Background/Objectives: Standard-of-care influenza vaccines contain antigens that are typically derived from components of wild type (WT) influenza viruses. Often, these antigens elicit strain-specific immune responses and are susceptible to mismatch in seasons where antigenic drift is prevalent. Thanks to advances in viral surveillance and sequencing, influenza vaccine antigens can now be optimized using computationally derived methodologies and algorithms to enhance their immunogenicity. Methods: Mice and ferrets that had been previously exposed to historical H1N1 and H3N2 influenza viruses were vaccinated intramuscularly with bivalent mixtures of H1 and H3 recombinant hemagglutinin (rHA) proteins, which were generated using a computationally optimized broadly reactive antigen (COBRA) design methodology. The vaccine antigens were mixed with a cationic lipid nanoparticle adjuvant, Infectimune®, which promotes both humoral and cellular immune responses. Results: Mice and ferrets vaccinated with Infectimune® and COBRA rHAs elicited protective antibody titers against panels of H1N1 and H3N2 influenza viruses isolated over the past 10 years. These animals also had antibodies that neutralized numerous modern H1N1 and H3N2 influenza viruses in vitro. When challenged with the A/Victoria/2570/2019 H1N1 influenza virus, the COBRA rHA vaccinated animals had minimal weight loss, and no detectable virus was present in their respiratory tissues on day 3 post-infection. Conclusions: These results demonstrate that COBRA rHA vaccines formulated with Infectimune® elicit protective antibody responses against influenza strains, which were isolated across periods of time when standard-of-care vaccines were frequently reformulated, thus reducing the need to update vaccines on a nearly annual basis.
Background/Objectives: There is a need for effective seasonal influenza virus vaccines that provide broad and long-lasting protection against influenza virus infections. Methods: In this study, next-generation influenza hemagglutinin (HA) and neuraminidase (NA) vaccine candidates designed using the computationally optimized broadly reactive antigen (COBRA) methodology were formulated with the TLR9 agonist, CpG 1018. These adjuvanted COBRA HA/NA vaccines were administered intramuscularly or intranasally to mice with pre-existing anti-influenza immunity or immunologically naïve mice. Results: Mice with pre-existing immune responses to historical influenza virus strains vaccinated intranasal (IN) with COBRA HA/NA vaccines adjuvanted with CpG 1018 had enhanced IgG titers in their bronchoalveolar lavages (BALF) compared to unadjuvanted vaccines. These mice also had increased serum IgG titers that were like antibody titers observed in mice that were vaccinated intramuscularly. Mice that were vaccinated intranasally with this adjuvanted vaccine also had antibodies with significantly higher hemagglutination inhibition activity against a broad range of H1N1 and H3N2 influenza viruses and more HA and NA specific antibody-secreting cells compared to unadjuvanted vaccine. Following the H1N1 influenza virus challenge, pre-immune mice that were vaccinated with the COBRA HA/NA vaccine with CpG 1018 were protected from morbidity and mortality and had no detectable viral lung titers. Conclusions: Overall, CpG 1018 adjuvanted COBRA HA/NA elicited enhanced protective antibodies compared to the unadjuvanted vaccine against several drifted H1N1 and H3N2 influenza viruses in pre-immune mice that were either intramuscularly or intranasally vaccinated with a balanced Th1/Th2 immune response.
23 June 2026 in Comparative Immunology, Microbiology and Infectious Diseases
Influenza viruses cause seasonal epidemics resulting in substantial morbidity and mortality, particularly in the elderly population. Although annual high-dose or adjuvanted influenza vaccines help maintain antibody titers in individuals aged 65 years and older, vaccine-mismatched strains, especially H3N2 influenza viruses, often lead to severe disease. Therefore, a universal influenza vaccine capable of eliciting broadly protective immunity in older individuals is urgently needed. Here, Computationally Optimized Broadly Reactive Antigen (COBRA) based H1 and H3 hemagglutinin (HA) vaccines formulated with the clinical-stage investigational immune modulator Infectimune were evaluated in pre-immune young (9 months) and elderly (50–71 months) ferrets to assess age-related differences in antibody responses. COBRA HA vaccination elicited robust H1- and H3- HA-specific antibody responses in both age groups. Following a single immunization, young ferrets developed significantly higher IgG titers than elderly ferrets, however, booster immunization with COBRA HA vaccines formulated with Infectimune increased anti-HA antibody titers in elderly animals to levels comparable to those of young ferrets. Upon influenza virus challenge, pre-immune young ferrets were largely protected against virally induced disease with minimal weight loss and reduced viral shedding, regardless if the ferrets were vaccinated with COBRA HA proteins or mock vaccinated. In contrast, only elderly ferrets receiving COBRA HA vaccines formulated with Infectimune were protected following challenge with significantly less body weight loss and lower nasal viral titers. These findings demonstrate that COBRA HA vaccines induce broad antibody responses in young and aged hosts and the addition of Infectimune enhanced vaccine efficacy in aged ferrets.